Psychopharmacological neuroprotection in neurodegenerative disease: Heuristic clinical applications

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 22, Issue 2, 2010, Pages 130-154

  Lauterbach, Edward C ^a   Shillcutt, Samuel D ^b   Victoroff, Jeff ^c,d   Coburn, Kerry L ^b   Mendez, Mario F ^e  

^a MERCER UNIVERSITY   (United States)

^b MERCER UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d RANCHO LOS AMIGOS NATIONAL REHABILITATION CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ADENOSINE TRIPHOSPHATE; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DULOXETINE; FLUOXETINE; GLUTAMIC ACID; IMIPRAMINE; MELATONIN; MESSENGER RNA; MODAFINIL; PAROXETINE; PSYCHOTROPIC AGENT; RAMELTEON; S ZOPICLONE; UNCLASSIFIED DRUG; ZIPRASIDONE; ZOPICLONE;

AGGRESSION; AGITATION; AKINESIA; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT ACTIVITY; ANXIETY; APATHY; APOPTOSIS; ATTENTION; BRADYPHRENIA; CELL LINE; CELL PROLIFERATION; CLINICAL TRIAL; COGNITION; DAYTIME SOMNOLENCE; DEGENERATIVE DISEASE; DELIRIUM; DELUSION; DEMENTIA; DEPRESSION; DOSE RESPONSE; DRUG HALF LIFE; DYSKINESIA; EPISODIC MEMORY; EXCITEMENT; FATIGUE; FREEZING; HUMAN; HUNTINGTON CHOREA; IMPULSIVENESS; IN VIVO STUDY; INSOMNIA; INTOXICATION; IRRITABILITY; LIPID PEROXIDATION; MEMORY; MENTAL DISEASE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHARMACODYNAMICS; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; PSYCHOPATHY; PSYCHOPHARMACOLOGY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SLEEP; URINE INCONTINENCE; WANDERING BEHAVIOR;

EID: 77952400184     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.2010.22.2.130     Document Type: Review

References (469)

1. Aarsland D, Sharp S, Ballard C: Psychiatric and behavioral symptoms in Alzheimer's disease and other dementias: etiology and management. Curr Neurol Neurosci Rep 2005; 5:345-354 (Pubitemid 41419324)
2. Anderson KE, Marshall FJ: Behavioral symptoms associated with Huntington's disease. Adv Neurol 2005; 96:197-208
3. Aupperle P: Management of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics. Am J Alzheimers Dis Other Demen 2006; 21:101-108
4. Boyle PA, Malloy PF: Treating apathy in Alzheimer's disease. Dement Geriatr Cogn Disord 2004; 17:91-99
5. Brodaty H, Draper B, Saab D, et al: Psychosis, depression and behavioral disturbances in Sydney nursing home residents: prevalence and predictors. Int J Geriatr Psychiatry 2001; 16:504-512 (Pubitemid 32492385)
6. Brodaty H, Low LF: Aggression in the elderly. J Clin Psychiatry 2003; 64(suppl 4):36-43
7. Burgut FT, Benaur M, Hencliffe C: Late-life depression: a neuropsychiatric approach. Expert Rev Neurother 2006; 6:65-72
8. Buhr GT, White HK: Difficult behaviors in long-term care patients with dementia. J Am Med Dir Assoc 2007; 8(suppl 2):e101-113
9. Burns A, De Deyn PP: Risperidone for the treatment of neuropsychiatric features in dementia. Drugs Aging 2006; 23:887-896 (Pubitemid 44788141)
10. Fischer C, Bozanovic-Sosic R, Norris M: Review of delusions in dementia. Am J Alzheimers Dis Other Demen 2004; 19:19-23
11. Fischer C, Bozanovic R, Atkins JH, et al: Treatment of delusions in Alzheimer's disease: response to pharmacotherapy. Dement Geriatr Cogn Disord 2006; 22:260-266 (Pubitemid 44310523)
12. Fischer C, Bozanovic R, Atkins JH, et al: Treatment of delusions in dementia with Lewy bodies: response to pharmacotherapy. Dement Geriatr Cogn Disord 2007; 23:307-311 (Pubitemid 46631936)
13. Kozman MN, Wattis J, Curran S: Pharmacological management of behavioral and psychological disturbance in dementia. Hum Psychopharmacol 2006; 21:1-12 (Pubitemid 43192471)
14. Kurt A, Nijboer F, Matuz T, et al: Depression and anxiety in individuals with amyotrophic lateral sclerosis: epidemiology and management. CNS Drugs 2007; 21:279-291 (Pubitemid 46598449)
15. Lauterbach EC: The neuropsychiatry of Parkinson's disease and related disorders. Psychiatr Clin North Am 2004; 27:801-825 (Pubitemid 39535129)
16. Lauterbach EC: The neuropsychiatry of Parkinson's disease. Minerva Medica 2005; 96:155-173
17. Lee HB, Lyketsos CG: Depression in Alzheimer's disease: heterogeneity and related issues. Biol Psychiatry 2003; 54:353-362 (Pubitemid 37270616)
18. Lesser JM, Hughes S: Psychosis-related disturbances: psychosis, agitation, and disinhibition in Alzheimer's disease: definitions and treatment options. Geriatrics 2006; 61:14-20
19. Lyketsos CG, Lee HB: Diagnosis and treatment of depression in Alzheimer's disease: a practical update for the clinician. Dement Geriatr Cogn Disord 2004; 17:55-64 (Pubitemid 37499969)
20. McKeith I, Cummings J: Behavioral changes and psychological symptoms in dementia disorders. Lancet Neurol 2005; 4:735-742 (Pubitemid 41457289)
21. Mendez MF, Lauterbach EC, Sampson SM, ANPA Committee on Research: An evidence-based review of the psychopathology of frontotemporal dementia: a report of the ANPA Committee on Research. J Neuropsychiatry Clin Neurosci 2008; 20:130-149
22. Mizrahi R, Starkstein SE: Epidemiology and management of apathy in patients with Alzheimer's disease. Drugs Aging 2007; 24:547-554 (Pubitemid 47195674)
23. Overshott R, Byrne J, Burns A: Nonpharmacological and pharmacological interventions for symptoms in Alzheimer's disease. Expert Rev Neurother 2004; 4:809-821 (Pubitemid 39186686)
24. Pace-Savitsky CE, Johnson JK, Miller BL: Behavioral changes in frontotemporal dementia with parkinsonism. Adv Neurol 2005; 96:187-196
25. Potter GG, Steffens DC: Contribution of depression to cognitive impairment and dementia in older adults. Neurologist 2007; 13:105-117 (Pubitemid 46743077)
26. Pulsford D, Duxbury J: Aggressive behavior by people with dementia in residential care settings: a review. J Psychiatr Ment Health Nurs 2006; 13:611-618 (Pubitemid 44352642)
27. Ropacki SA, Jeste DV: Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry 2005; 162:2022-2030
28. Rosenblatt A: Neuropsychiatry of Huntington's disease. Dialogues Clin Neurosci 2007; 9:191-197
29. Starkstein SE, Mizrahi R: Depression in Alzheimer's disease. Expert Rev Neurother 2006; 6:887-895
30. Alexopoulos GS, Jeste DV, Chung H, et al: Treatment of Dementia and Its Behavioral Disturbances. Minneapolis, McGraw-Hill, 2005
31. Ballard C, Howard R: Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci 2006; 7:492-500 (Pubitemid 44012289)
32. Caine ED: Clinical perspectives on atypical antipsychotics for treatment of agitation. J Clin Psychiatry 2006; 67(suppl 10):22-31 (Pubitemid 44433623)
33. Herrmann N, Lanctot KL: Pharmacologic management of neuropsychiatric symptoms of Alzheimer disease. Can J Psychiatry 2007; 52:630-646 (Pubitemid 350085594)
34. Lee PE, Gill SS, Freedman M, et al: Atypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review. BMJ 2004; 329:75 (Pubitemid 38901571)
35. Madhusoodanan S, Shah P, Brenner R, et al: Pharmacological treatment of the psychosis of Alzheimer's disease: what is the best approach? CNS Drugs 2007; 21:101-115
36. Moretti R, Torre P, Antonello RM, et al: Atypical neuroleptics as a treatment of agitation and anxiety in Alzheimer's disease: risks or benefits. Expert Rev Neurother 2006; 6:705-710 (Pubitemid 43961874)
37. Rummans TA, Lauterbach EC, Coffey CE, et al: Pharmacologic efficacy in neuropsychiatry: a review of placebo-controlled treatment trials. A report of the ANPA Committee on Research. J Neuropsychiatry Clin Neurosci 1999; 11:176-189
38. Wang PS, Brookhart MA, Setoguchi S, et al: Psychotropic medication use for behavioral symptoms of dementia. Curr Neurol Neurosci Rep 2006; 6:490-495 (Pubitemid 44742117)
39. Kozikowski AP, Gaisina IN, Petukhov PA, et al: Highly potent and specific GSK-3beta inhibitors that block tau phosphorylation and decrease alpha-synuclein protein expression in a cellular model of Parkinson's disease. ChemMedChem 2006; 1:256-266
40. Rockenstein E, Torrance M, Adame A, et al: Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 2007; 27:1981-1991 (Pubitemid 46310321)
41. Brion JP, Anderton BH, Authelet M, et al: Neurofibrillary tangles and tau phosphorylation. Biochem Soc Symp 2001; 67:81-88
42. Nussbaum RL, Ellis CE: Alzheimer's disease and Parkinson's disease. N Engl J Med 2003; 348:1356-1364
43. Ballard C, Ziabreva I, Perry R, et al: Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 2006; 67:1931-1934 (Pubitemid 44967366)
44. Selkoe DJ, Schenk D: Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003; 43:545-584
45. Cummings JL: Alzheimer's disease. N Engl J Med 2004; 351:56-67
46. Buratti E, Baralle FE: Multiple roles of TDP-43 in gene expression, splicing regulation, and human disease. Front Biosci 2008; 13:867-878 (Pubitemid 351594732)
47. Liscic RM, Grinberg LT, Zidar J, et al: ALS and FTLD: two faces of TDP-43 proteinopathy. Eur J Neurol 2008; 15:772-780
48. Kulstad JJ, Green PS, Cook DG, et al: Differential modulation of plasma beta-amyloid by insulin in patients with Alzheimer disease. Neurology 2006; 66:1506-1510
49. Flicker L, Martins RN, Thomas J, et al: B-vitamins reduce plasma levels of beta amyloid. Neurobiol Aging 2008; 29:303-305
50. Gurol ME, Irizarry MC, Smith EE, et al: Plasma beta-amyloid and white matter lesions in AD, MCI, and cerebral amyloid angiopathy. Neurology 2006; 66:23-29
51. El-Agnaf OM, Salem SA, Paleologou KE, et al: Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J 2006; 20:419-425
52. Lee PH, Lee G, Park HJ, et al: The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J Neural Transm 2006; 113:1435-1439 (Pubitemid 44435881)
53. Pesaresi M, Lovati C, Bertora P, et al: Plasma levels of beta-amyloid (1- 42) in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging 2006; 27:904-905
54. Graff-Radford NR, Crook JE, Lucas J, et al: Association of low plasma abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol 2007; 64:354-362 (Pubitemid 46425689)
55. Li QX, Mok SS, Laughton KM, et al: Plasma alpha-synuclein is decreased in subjects with Parkinson's disease. Exp Neurol 2007; 204:583-588 (Pubitemid 46497045)
56. Layfield R, Cavey JR, Lowe J: Role of ubiquitin-mediated proteolysis in the pathogenesis of neurodegenerative disorders. Ageing Res Rev 2003; 2:343-356 (Pubitemid 37159397)
57. Lopez Salon M, Pasquini L, Besio MM, et al: Relationship between beta-amyloid degradation and the 26S proteasome in neural cells. Exp Neurol 2003; 180:131-143 (Pubitemid 36398168)
58. Almeida CG, Takahashi RH, Gouras GK: Beta-amyloid accumulation impairs multivesicular body sorting by inhibiting the ubiquitin-proteasome system. J Neurosci 2006; 26:4277-4288
59. Hoshi M, Takashima A, Noguchi K, et al: Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. Proc Natl Acad Sci U S A 1996; 93:2719-2723 (Pubitemid 26114315)
60. Feany MB: New genetic insights into Parkinson's disease. N Engl J Med 2004; 351:1937-1940 (Pubitemid 39447134)
61. Hölscher C: Development of beta-amyloid-induced neurodegeneration in Alzheimer's disease and novel neuroprotective strategies. Rev Neurosci 2005; 16:181-212 (Pubitemid 41655771)
62. Migliore L, Fontana I, Colognato R, et al: Searching for the role and the most suitable biomarkers of oxidative stress in Alzheimer's disease and in other neurodegenerative diseases. Neurobiol Aging 2005; 26:567-573 (Pubitemid 40228750)
63. Michaelis ML: Ongoing in vivo studies with cytoskeletal drugs in tau transgenic mice. Curr Alzheimer Res 2006; 3:215-219
64. Jenner P: Oxidative stress in Parkinson's disease. Ann Neurol 2003; 53(suppl 3):S26-S36
65. Thompson SJ, Loftus LT, Ashley MD, et al: Ubiquitin-proteasome system as a modulator of cell fate. Curr Opin Pharmacol 2008; 8:90-95
66. Coleman MP, Ribchester RR: Programmed axon death, synaptic dysfunction and the ubiquitin proteasome system. Curr Drug Targets CNS Neurol Disord 2004; 3:227-238 (Pubitemid 38854917)
67. Orrenius S, Gogvadze V, Zhivotovsky B: Mitochondrial oxidative stress: implications for cell death. Annu Rev Pharmacol Toxicol 2007; 47:143-183 (Pubitemid 46272127)
68. Perier C, Tieu K, Guégan C, et al: Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proc Natl Acad Sci U S A 2005; 102:19126-19131 (Pubitemid 43049577)
69. Senoo-Matsuda N, Hartman PS, Akatsuka A, et al: A complex II defect affects mitochondrial structure, leading to ced-3- and ced-4-dependent apoptosis and aging. J Biol Chem 2003; 278:22031-22036 (Pubitemid 36792612)
70. Ishii T, Yasuda K, Akatsuka A, et al: A mutation in the SDHC gene of complex II increases oxidative stress, resulting in apoptosis and tumorigenesis. Cancer Res 2005; 65:203-209 (Pubitemid 40070811)
71. Li N, Ragheb K, Lawler G, et al: Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. J Biol Chem 2003; 278:8516-8525 (Pubitemid 36800604)
72. Higuchi M, Proske RJ, Yeh ET: Inhibition of mitochondrial respiratory chain complex I by TNF results in cytochrome c release, membrane permeability transition, and apoptosis. Oncogene 1998; 17:2515-2524 (Pubitemid 28544721)
73. Rotilio G, Aquilano K, Ciriolo MR: Interplay of Cu,Zn superoxide dismutase and nitric oxide synthase in neurodegenerative processes. IUBMB Life 2003; 55:629-634 (Pubitemid 38019842)
74. Agil A, Duran R, Barrero F, et al: Plasma lipid peroxidation in sporadic Parkinson's disease: role of the l-dopa. J Neurol Sci 2006; 240:31-36 (Pubitemid 41814950)
75. Okuno T, Nakatsuji Y, Kumanogoh A, et al: Loss of dopaminergic neurons by the induction of inducible nitric oxide synthase and cyclooxygenase-2 via CD 40: relevance to Parkinson's disease. J Neurosci Res 2005; 81:874-882 (Pubitemid 41532153)
76. Pannu R, Singh I: Pharmacological strategies for the regulation of inducible nitric oxide synthase: neurodegenerative versus neuroprotective mechanisms. Neurochem Int 2006; 49:170-182 (Pubitemid 43867075)
77. Clark CB, Zhang Y, Martin SM, et al: The nitric oxide synthase inhibitor N(G)-nitro-L-arginine decreases defibrillation- induced free radical generation. Resuscitation 2004; 60:351-357 (Pubitemid 36369237)
78. Gomez-Vargas M, Nishibayashi-Asanuma S, Asanuma M, et al: Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain. Brain Res 1998; 790:202-208 (Pubitemid 28234504)
79. Tatton WG, Chalmers-Redman R, Brown D, et al: Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol 2003; 53(suppl 3):S61-S70 (Pubitemid 36368563)
80. Charriaut-Marlangue C: Apoptosis: a target for neuroprotection. Therapie 2004; 59:185-190
81. Lemasters JJ, Qian T, Trost LC, et al: Confocal microscopy of the mitochondrial permeability transition in necrotic and apoptotic cell death. Biochem Soc Symp 1999; 66:205-222 (Pubitemid 129639033)
82. Zhang JH, Xu M: DNA fragmentation in apoptosis. Cell Res 2000; 10:205-211
83. Krieger C, Duchen MR: Mitochondria, Ca2+ and neurodegenerative disease. Eur J Pharmacol 2002; 447:177-188
84. Hynd MR, Scott HL, Dodd PR: Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int 2004; 45:583-595 (Pubitemid 38844879)
85. Oh JD, Chase TN: Glutamate-mediated striatal dysregulation and the pathogenesis of motor response complications in Parkinson's disease. Amino Acids 2002; 23:133-139
86. Marino MJ, Valenti O, Conn PJ: Glutamate receptors and Parkinson's disease: opportunities for intervention. Drugs Aging 2003; 20:377-397 (Pubitemid 36520959)
87. Arzberger T, Krampfl K, Leimgruber S, et al: Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington's disease: an in situ hybridization study. J Neuropathol Exp Neurol 1997; 56:440-454 (Pubitemid 27465027)
88. Wu J, Tang T, Bezprozvanny I: Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease. Neurosci Lett 2006; 407:219-223 (Pubitemid 44402868)
89. Ludolph AC, Meyer T, Riepe MW, et al: Amyotrophic lateral sclerosis and glutamate. Restor Neurol Neurosci 1998; 13:59-67
90. Iwasaki Y, Ikeda K, Kinoshita M: Molecular and cellular mechanism of glutamate receptors in relation to amyotrophic lateral sclerosis. Curr Drug Targets CNS Neurol Disord 2002; 1:511-518
91. Molinuevo JL, Llado A, Rami L: Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias. Am J Alzheimers Dis Other Demen 2005; 20:77-85
92. Lamanauskas N, Nistri A: Riluzole blocks persistent Na+ and Ca2+ currents and modulates release of glutamate via presynaptic NMDA receptors on neonatal rat hypoglossal motoneurons in vitro. Eur J Neurosci 2008; 27:2501-2514 (Pubitemid 351781658)
93. Nucci C, Piccirilli S, Bagetta G, et al: N-methyl-D-aspartate (NMDA) and non-NMDA glutamate receptor antagonists protect from apoptosis induced in the lateral geniculate nucleus of rabbits exposed to the dark. Neurosci Lett 1997; 229:185-188 (Pubitemid 27316077)
94. Mailly F, Marin P, Israël M, et al: Increase in external glutamate and NMDA receptor activation contribute to H2O2-induced neuronal apoptosis. J Neurochem 1999; 73:1181-1188 (Pubitemid 29395477)
95. Lu WY, Jackson MF, Bai D, et al: In CA1 pyramidal neurons of the hippocampus protein kinase C regulates calcium-dependent inactivation of NMDA receptors. J Neurosci 2000; 20:4452-4461
96. Nikolova S, Lee YS, Lee YS, et al: Rac1-NADPH oxidase-regulated generation of reactive oxygen species mediates glutamate-induced apoptosis in SH-SY5Y human neuroblastoma cells. Free Radic Res 2005; 39:1295-1304 (Pubitemid 43023794)
97. Nishimoto T, Kihara T, Akaike A, et al: Alpha-amino-3-hydroxy-5-methyl-4- isoxazole propionate attenuates glutamate-induced caspase-3 cleavage via regulation of glycogen synthase kinase 3beta. J Neurosci Res 2008; 86:1096-1105 (Pubitemid 351441307)
98. Benveniste EN, Nguyen VT, O'Keefe GM: Immunological aspects of microglia: relevance to Alzheimer's disease. Neurochem Int 2001; 39:381-391 (Pubitemid 32907402)
99. Hirsch EC, Hunot S, Hartmann A: Neuroinflammatory processes in Parkinson's disease. Parkinsonism Relat Disord 2005; 11(suppl 1):S9-S15
100. Wersinger C, Sidhu A: An inflammatory pathomechanism for Parkinson's disease? Curr Med Chem 2006; 13:591-602
101. Liu Y, Qin L, Li G, et al: Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J Pharmacol Exp Ther 2003; 305:212-218 (Pubitemid 36373853)
102. Cirelli C, Faraguna U, Tononi G: Changes in brain gene expression after long-term sleep deprivation. J Neurochem 2006; 98:1632-1645 (Pubitemid 44200452)
103. Benitez-King G, Ramírez-Rodríguez G, Ortíz L, et al: The neuronal cytoskeleton as a potential therapeutical target in neurodegenerative diseases and schizophrenia. Curr Drug Targets CNS Neurol Disord 2004; 3:515-533 (Pubitemid 40081279)
104. Grundman M, Capparelli E, Kim HT, et al: A multicenter, randomized, placebo controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients. Life Sci 2003; 73:539-553 (Pubitemid 36603333)
105. Kells AP, Fong DM, Dragunow M, et al: AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of Huntington's disease. Mol Ther 2004; 9:682-688 (Pubitemid 38660421)
106. Weinreb O, Amit T, Bar-Am O, et al: Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann N Y Acad Sci 2007; 1122:155-168 (Pubitemid 350249546)
107. Zurn AD, Winkel L, Menoud A, et al: Combined effects of GDNF, BDNF, and CNTF on motoneuron differentiation in vitro. J Neurosci Res 1996; 44:133-141 (Pubitemid 26134404)
108. Ray DE: CINP 2000: Collegium Internationale Neuro Psychopharmacologicum 22nd Congress. IDrugs 2000; 3:1023-1025
109. Sun M, Kong L, Wang X, et al: Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease. Brain Res 2005; 1052:119-129 (Pubitemid 41116769)
110. Hisaoka K, Takebayashi M: [Glia as targets for antidepressants: an involvement in glial cell line-derived neurotrophic factor.] Nihon Shinkei Seishin Yakurigaku Zasshi 2007; 27:173-179 (Japanese)
111. Akerud P, Holm PC, Castelo-Branco G, et al: Persephin-overexpressing neural stem cells regulate the function of nigral dopaminergic neurons and prevent their degeneration in a model of Parkinson's disease. Mol Cell Neurosci 2002; 21:205-222 (Pubitemid 35333813)
112. Giasson BI, Forman MS, Higuchi M, et al: Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 2003; 300:636-640 (Pubitemid 36520587)
113. Kwok JB, Hallupp M, Loy CT, et al: GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. Ann Neurol 2005; 58:829-839 (Pubitemid 41746872)
114. Goris A, Williams-Gray CH, Clark GR, et al: Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol 2007; 62:145-153 (Pubitemid 47546500)
115. Sahin HA, Emre M, Ziabreva I, et al: The distribution pattern of pathology and cholinergic deficits in amygdaloid complex in Alzheimer's disease and dementia with Lewy bodies. Acta Neuropathol (Berl) 2006; 111:115-125
116. Giasson BI, Lee VM, Trojanowski JQ: Interactions of amyloidogenic proteins. Neuromolecular Med 2003; 4:49-58
117. Yuan Y, Jin J, Yang B, et al: Overexpressed alpha-synuclein regulated the nuclear factor-kappaB signal pathway. Cell Mol Neurobiol 2008; 28:21-33 (Pubitemid 351251003)
118. Ekshyyan O, Aw TY: Apoptosis: a key in neurodegenerative disorders. Curr Neurovasc Res 2004; 1:355-371
119. Avraham E, Szargel R, Eyal A, et al: Glycogen synthase kinase 3beta modulates synphilin-1 ubiquitylation and cellular inclusion formation by SIAH: implications for proteasomal function and Lewy body formation. J Biol Chem 2005; 280:42877-42886 (Pubitemid 43049250)
120. King TD, Bijur GN, Jope RS: Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3beta and attenuated by lithium. Brain Res 2001; 919:106-114
121. Chen G, Bower KA, Ma C, et al: Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J 2004; 18:1162-1164 (Pubitemid 39561557)
122. Wang W, Yang Y, Ying C, et al: Inhibition of glycogen synthase kinase-3beta protects dopaminergic neurons from MPTP toxicity. Neuropharmacology 2007; 52:1678-1684 (Pubitemid 46843143)
123. Bychkov E, Ahmed MR, Dalby KN, et al: Dopamine depletion and subsequent treatment with l-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum. J Neurochem 2007; 102:699-711 (Pubitemid 47057295)
124. Koh SH, Song C, Noh MY, et al: Inhibition of glycogen synthase kinase-3 reduces l-dopa-induced neurotoxicity. Toxicology 2008; 247:112-118
125. Mani RB: The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint. Stat Med 2004; 23:305-314
126. Mignot E, Nishino S, Guilleminault C, et al: Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994; 17:436-437 (Pubitemid 24271517)
127. Wisor JP, Nishino S, Sora I, et al: Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001; 21:1787-1794
128. Madras BK, Xie Z, Lin Z, et al: Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 2006; 319:561-569
129. Korotkova TM, Klyuch BP, Ponomarenko AA, et al: Modafinil inhibits rat midbrain dopaminergic neurons through D2-like receptors. Neuropharmacology 2007; 52:626-633
130. Nishino S, Mao J, Sampathkumaran R, et al: Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants. Sleep Res Online 1998; 1:49-61
131. Taneja I, Diedrich A, Black BK, et al: Modafinil elicits sympathomedullary activation. Hypertension 2005; 45:612-618
132. Hou RH, Freeman C, Langley RW, et al: Does modafinil activate the locus coeruleus in man? Comparison of modafinil and clonidine on arousal and autonomic functions in human volunteers. Psychopharmacology (Berl) 2005; 181:537-549 (Pubitemid 41480903)
133. Högl B, Saletu M, Brandauer E, et al: Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 2002; 25:905-909 (Pubitemid 35424536)
134. Carter GT, Weiss MD, Lou JS, et al: Modafinil to treat fatigue in amyotrophic lateral sclerosis: an open label pilot study. Am J Hosp Palliat Care 2005; 22:55-59
135. Randall DC, Fleck NL, Shneerson JM, et al: The cognitive-enhancing properties of modafinil are limited in non-sleep-deprived middle-aged volunteers. Pharmacol Biochem Behav 2004; 77:547-555
136. Ferraro L, Antonelli T, Tanganelli S, et al: The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. Neuropsychopharmacology 1999; 20:346-356 (Pubitemid 29099765)
137. Whitlock JR, Heynen AJ, Shuler MG, et al: Learning induces long-term potentiation in the hippocampus. Science 2006; 313:1093-1097 (Pubitemid 44300229)
138. Zhong WX, Dong ZF, Tian M, et al: N-methyl-D-aspartate receptor-dependent long-term potentiation in CA1 region affects synaptic expression of glutamate receptor subunits and associated proteins in the whole hippocampus. Neuroscience 2006; 141:1399-1413 (Pubitemid 44128681)
139. Taylor FB, Russo J: Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol 2000; 10:311-320 (Pubitemid 32103907)
140. Turner DC, Clark L, Dowson J, et al: Modafinil improves cognition and response inhibition in adult attention-deficit/hyperactivity disorder. Biol Psychiatry 2004; 55:1031-1040 (Pubitemid 38581919)
141. Turner DC, Clark L, Pomarol-Clotet E, et al: Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 2004; 29:1363-1373 (Pubitemid 38780659)
142. Schwartz JR, Nelson MT, Schwartz ER, et al: Effects of modafinil on wakefulness and executive function in patients with narcolepsy experiencing late-day sleepiness. Clin Neuropharmacol 2004; 27:74-79
143. Walsh JK, Randazzo AC, Stone KL, et al: Modafinil improves alertness, vigilance, and executive function during simulated night shifts. Sleep 2004; 27:434-439
144. Turner DC, Robbins TW, Clark L, et al: Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology (Berl) 2003; 165:260-269 (Pubitemid 36197601)
145. Hunter MD, Ganesan V, Wilkinson ID, et al: Impact of modafinil on prefrontal executive function in schizophrenia. Am J Psychiatry 2006; 163:2184-2186 (Pubitemid 46114242)
146. Biederman J, Swanson JM, Wigal SB, et al: Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 2005; 116:777-784 (Pubitemid 46056456)
147. Swanson JM, Greenhill LL, Lopez FA, et al: Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry 2006; 67:137-147 (Pubitemid 43213294)
148. Greenhill LL, Biederman J, Boellner SW, et al: A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006; 45:503-511 (Pubitemid 43756179)
149. Biederman J, Swanson JM, Wigal SB, et al: A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study. J Clin Psychiatry 2006; 67:727-735 (Pubitemid 43946179)
150. Randall DC, Viswanath A, Bharania P, et al: Does modafinil enhance cognitive performance in young volunteers who are not sleep-deprived? J Clin Psychopharmacol 2005; 25:175-179
151. Schillerstrom JE, Seaman JS: Modafinil augmentation of mirtazapine in a failure-to-thrive geriatric inpatient. Int J Psychiatry Med 2002; 32:405-410
152. Padala PR, Burke WJ, Bhatia SC: Modafinil therapy for apathy in an elderly patient. Ann Pharmacother 2007; 41:346-349
153. Carter GT, Han JJ, Mayadev A, et al: Modafinil reduces fatigue in Charcot-Marie-Tooth disease type 1A: a case series. Am J Hosp Palliat Care 2006; 23:412-416
154. Fava M, Thase ME, DeBattista C: A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005; 66:85-93
155. Rasmussen NA, Schroder P, Olsen LR, et al: Modafinil augmentation in depressed patients with partial response to antidepressants: a pilot study on self-reported symptoms covered by the Major Depression Inventory (MDI) and the Symptom Checklist (SCL-92). Nord J Psychiatry 2005; 59:173-178 (Pubitemid 40946275)
156. Thase ME, Fava M, DeBattista C, et al: Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, openlabel, extension study. CNS Spectr 2006; 11:93-102 (Pubitemid 43306504)
157. Vaishnavi S, Gadde K, Alamy S, et al: Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment. J Clin Psychopharmacol 2006; 26:373-378 (Pubitemid 44187638)
158. Ferraro L, Antonelli T, O'Connor WT, et al: The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission. Neurosci Lett 1998; 253:135-138 (Pubitemid 28430641)
159. Antonelli T, Ferraro L, Hillion J, et al: Modafinil prevents glutamate cytotoxicity in cultured cortical neurons. Neuroreport 1998; 9:4209-4213 (Pubitemid 29030716)
160. Jenner P, Zeng BY, Smith LA, et al: Antiparkinsonian and neuroprotective effects of modafinil in the MPTP-treated common marmoset. Exp Brain Res 2000; 133:178-188 (Pubitemid 30449903)
161. van Vliet SA, Vanwersch RA, Jongsma MJ, et al: Neuroprotective effects of modafinil in a marmoset Parkinson model: behavioral and neurochemical aspects. Behav Pharmacol 2006; 17:453-462
162. Xiao YL, Fu JM, Dong Z, et al: Neuroprotective mechanism of modafinil on Parkinson disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Acta Pharmacol Sin 2004; 25:301-305
163. Aguirre JA, Cintra A, Hillion J, et al: A stereological study on the neuroprotective actions of acute modafinil treatment on 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced nigral lesions of the male black mouse. Neurosci Lett 1999; 275:215-218
164. Bymaster FP, Lee TC, Knadler MP, et al: The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des 2005; 11:1475-1493
165. Raskin J, Wiltse CG, Siegal A, et al: Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry 2007; 164:900-909 (Pubitemid 46972905)
166. Nyth AL, Gottfries CG: The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: a Nordic multicentre study. Br J Psychiatry 1990; 157:894-901
167. Alexopoulos GS, Jeste DV, Chung H, et al: The expert consensus guideline series. Treatment of dementia and its behavioral disturbances: Introduction: methods, commentary, and summary. Postgrad Med 2005; Spec No:6-22
168. Thompson S, Herrmann N, Rapoport MJ, et al: Efficacy and safety of antidepressants for treatment of depression in Alzheimer's disease: a meta-analysis. Can J Psychiatry 2007; 52:248-255 (Pubitemid 46743472)
169. Richard IH: Depression in Parkinson's disease. Curr Treat Options Neurol 2000; 2:263-274
170. Shabnam GN, Th C, Kho D, et al: Therapies for depression in Parkinson's disease. Cochrane Database Syst Rev 2003; 3:CD003465
171. Chung TH, Deane KH, Ghazi-Noori S, et al: Systematic review of antidepressant therapies in Parkinson's disease. Parkinsonism Relat Disord 2003; 10:59-65 (Pubitemid 37476308)
172. Menza M, Marin H, Kaufman K, et al: Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition. J Neuropsychiatry Clin Neurosci 2004; 16:315-319 (Pubitemid 39244557)
173. Weintraub D, Taraborelli D, Morales KH, et al: Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study. J Neuropsychiatry Clin Neurosci 2006; 18:377-383
174. Lemke MR: Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002; 63:300-304 (Pubitemid 34456356)
175. Devos D, Dujardin K, Poirot I, et al: Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2008; 23:850-857
176. Pancrazi MP, Metais P: [Treatment of the psychological and behavioral disorders of Alzheimer's disease.] Presse Med 2005; 34:667-672 (French)
177. Tanaka M, Kita T: Paroxetine and improvement of visual hallucinations in patients with dementia with Lewy bodies. J Am Geriatr Soc 2005; 53:732-733 (Pubitemid 41623504)
178. Meco G, Bernardi S: Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:311-313 (Pubitemid 44959243)
179. Voon V, Lang AE: Antidepressants in the treatment of psychosis with comorbid depression in Parkinson's disease. Clin Neuropharmacol 2004; 27:90-92 (Pubitemid 38569182)
180. Sa DS, Kapur S, Lang AE: Amoxapine shows an antipsychotic effect but worsens motor function in patients with Parkinson's disease and psychosis. Clin Neuropharmacol 2001; 24:242-244 (Pubitemid 32717861)
181. Pollock BG, Mulsant BH, Rosen J, et al: A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psychiatry 2007; 15:942-952
182. Kurita M, Sato T, Nishino S, et al: Effects of fluvoxamine on behavioral and psychological symptoms of dementia in Alzheimer's disease: a report of three cases. Fukushima J Med Sci 2006; 52:143-148
183. Chalon S, Pereira A, Lainey E, et al: Comparative effects of duloxetine and desipramine on sleep EEG in healthy subjects. Psychopharmacology (Berl) 2005; 177:357-366 (Pubitemid 40228282)
184. Kluge M, Schüssler P, Steiger A: Duloxetine increases stage 3 sleep and suppresses rapid eye movement (REM) sleep in patients with major depression. Eur Neuropsychopharmacol 2007; 17:527-531 (Pubitemid 46755559)
185. Franco KN, Messinger-Rapport B: Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. J Am Med Dir Assoc 2006; 7:201-202 (Pubitemid 43273659)
186. Lanctôt KL, Herrmann N, van Reekum R, et al: Gender, aggression, and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease. Int J Geriatr Psychiatry 2002; 17:531-541 (Pubitemid 34678705)
187. Flint AJ, van Reekum R: The pharmacologic treatment of Alzheimer's disease: a guide for the general psychiatrist. Can J Psychiatry 1998; 43:689-697 (Pubitemid 28522724)
188. Leo RJ, Kim KY: Clomipramine treatment of paraphilias in elderly demented patients. J Geriatr Psychiatry Neurol 1995; 8:123-124
189. Swartz JR, Miller BL, Lesser IM, et al: Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 1997; 58:212-216 (Pubitemid 27242008)
190. Nyth AL, Gottfries CG, Lyby K, et al: A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 1992; 86:138-145
191. Greenwald BS, Kramer-Ginsberg E, Marin DB, et al: Dementia with coexistent major depression. Am J Psychiatry 1989; 146:1472-1478
192. Fregni F, Santos CM, Myczkowski ML, et al: Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75:1171-1174 (Pubitemid 39005779)
193. Munro CA, Brandt J, Sheppard JM, et al: Cognitive response to pharmacological treatment for depression in Alzheimer disease: secondary outcomes from the depression in Alzheimer's disease study (DIADS). Am J Geriatr Psychiatry 2004; 12:491-498 (Pubitemid 39181064)
194. Caballero J, Nahata MC: Atomoxetine hydrochloride for the treatment of attention-deficit/hyperactivity disorder. Clin Ther 2003; 25:3065-3083 (Pubitemid 38096145)
195. Buitelaar JK, Danckaerts M, Gillberg C, et al: A prospective, multicenter, open-label assessment of atomoxetine in non- North American children and adolescents with ADHD. Eur Child Adolesc Psychiatry 2004; 13:249-257 (Pubitemid 39279157)
196. Newman LA, Darling J, McGaughy J: Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex. Psychopharmacology (Berl) 2008; 200:39-50
197. Boggio PS, Fregni F, Bermpohl F, et al: Effect of repetitive TMS and fluoxetine on cognitive function in patients with Parkinson's disease and concurrent depression. Mov Disord 2005; 20:1178-1184 (Pubitemid 41632205)
198. Carboni E, Silvagni A: Dopamine reuptake by norepinephrine neurons: exception or rule? Crit Rev Neurobiol 2004; 16:121-128
199. Chatterjee A, Fahn S: Methylphenidate treats apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2002; 14:461-462
200. Roth RM, Flashman LA, McAllister TW: Apathy and its treatment. Curr Treat Options Neurol 2007; 9:363-370
201. Gasparini M, Fabrizio E, Bonifati V, et al: Cognitive improvement during tolcapone treatment in Parkinson's disease. J Neural Transm 1997; 104:887-894 (Pubitemid 27507335)
202. Tohgi H, Abe T, Takahashi S, et al: Monoamine metabolism in the cerebrospinal fluid in Parkinson's disease: relationship to clinical symptoms and subsequent therapeutic outcomes. J Neural Transm Park Dis Dement Sect 1993; 5:17-26 (Pubitemid 23038786)
203. Narabayashi H, Yokochi F, Ogawa T, et al: [Analysis of L-threo-3,4-dihydroxyphenylserine effect on motor and psychological symptoms in Parkinson's disease.] No To Shinkei 1991; 43:263-268 (Japanese)
204. Brotchie JM: Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov Disord 1998; 13:871-876
205. Kannari K, Kurahashi K, Tomiyama M, et al: [Tandospirone citrate, a selective 5-HT1A agonist, alleviates l-dopa-induced dyskinesia in patients with Parkinson's disease.] No To Shinkei 2002; 54:133-137 (Japanese)
206. Savola JM, Hill M, Engstrom M, et al: Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 2003; 18:872-883 (Pubitemid 37021161)
207. Thor KB, Katofiasc MA: Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose- anesthetized female cat. J Pharmacol Exp Ther 1995; 274:1014-1024
208. Nitti VW: Duloxetine: a new pharmacologic therapy for stress urinary incontinence. Rev Urol 2004; 6(suppl 3):S48-S55
209. Zahariou A, Papaioannou P, Kalogirou G: Is HCl duloxetine effective in the management of urinary stress incontinence after radical prostatectomy? Urol Int 2006; 77:9-12
210. Steers WD, Herschorn S, Kreder KJ, et al: Duloxetine compared with placebo for treating women with symptoms of overactive bladder. Br J Urology Internat 2007; 100:337-345 (Pubitemid 47036580)
211. Nelson RL, Guo Z, Halagappa VM, et al: Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Exp Neurol 2007; 205:166-176 (Pubitemid 46617502)
212. Li X, Rosborough KM, Friedman AB, et al: Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. Int J Neuropsychopharmacol 2007; 10:7-19 (Pubitemid 46122748)
213. Roh MS, Eom TY, Zmijewska AA, et al: Hypoxia activates glycogen synthase kinase-3 in mouse brain in vivo: protection by mood stabilizers and imipramine. Biol Psychiatry 2005; 57:278-286
214. Li X, Zhu W, Roh MS, et al: In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 2004; 29:1426-1431
215. Dong H, Goico B, Martin M, et al: Modulation of hippocampal cell proliferation, memory, and amyloid plaque deposition in APPsw (Tg2576) mutant mice by isolation stress. Neuroscience 2004; 127:601-609 (Pubitemid 38993164)
216. Nahon E, Israelson A, Abu-Hamad S, et al: Fluoxetine (Prozac) interaction with the mitochondrial voltage-dependent anion channel and protection against apoptotic cell death. FEBS Lett 2005; 579:5105-5110 (Pubitemid 41242861)
217. Chiou SH, Chen SJ, Peng CH, et al: Fluoxetine up-regulates expression of cellular FLICE-inhibitory protein and inhibits LPS-induced apoptosis in hippocampus-derived neural stem cell. Biochem Biophys Res Commun 2006; 343:391-400
218. Serafeim A, Grafton G, Chamba A, et al: 5-hydroxytryptamine drives apoptosis in biopsylike Burkitt lymphoma cells: reversal by selective serotonin reuptake inhibitors. Blood 2002; 99:2545-2553 (Pubitemid 34525444)
219. Bengel D, Isaacs KR, Heils A, et al: The appetite suppressant d-fenfluramine induces apoptosis in human serotonergic cells. Neuroreport 1998; 9:2989-2993 (Pubitemid 28555633)
220. Meredith EJ, Holder MJ, Chamba A, et al: The serotonin transporter (SLC6A4) is present in B-cell clones of diverse malignant origin: probing a potential anti-tumor target for psychotropics. FASEB J 2005; 19:1187-1189 (Pubitemid 40946460)
221. Lee HJ, Kim JW, Yim SV, et al: Fluoxetine enhances cell proliferation and prevents apoptosis in dentate gyrus of maternally separated rats. Mol Psychiatry 2001; 6:610, 725-728
222. Delgado PL, Miller HL, Salomon RM, et al: Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biol Psychiatry 1999; 46:212-220
223. Javors MA, Houston JP, Tekell JL, et al: Reduction of platelet serotonin content in depressed patients treated with either paroxetine or desipramine. Int J Neuropsychopharmacol 2000; 3:229-235
224. Rahmani M, Reese E, Dai Y, et al: Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 2005; 65:2422-2432 (Pubitemid 40490154)
225. Corda S, Laplace C, Vicaut E, et al: Rapid reactive oxygen species production by mitochondria in endothelial cells exposed to tumor necrosis factor-alpha is mediated by ceramide. Am J Respir Cell Mol Biol 2001; 24:762-768 (Pubitemid 32550600)
226. Therade-Matharan S, Laemmel E, Carpentier S, et al: Reactive oxygen species production by mitochondria in endothelial cells exposed to reoxygenation after hypoxia and glucose depletion is mediated by ceramide. Am J Physiol Regul Integr Comp Physiol 2005; 289:R1756-R1762 (Pubitemid 41643221)
227. Tang TS, Slow E, Lupu V, et al: Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc Natl Acad Sci U S A 2005; 102:2602-2607 (Pubitemid 40279423)
228. Tsao CW, Cheng JT, Lin YS: Down-regulation of Bcl-2, activation of caspases, and involvement of reactive oxygen species in 6-hydroxydopamine- induced thymocyte apoptosis. Neuroimmunomodulation 2002-2003; 10:328-336
229. Tsao CW, Cheng JT, Shen CL, et al: 6-hydroxydopamine induces thymocyte apoptosis in mice. J Neuroimmunol 1996; 65:91-95 (Pubitemid 26198091)
230. Muranaka S, Kanno T, Fujita H, et al: Involvement of ceramide in the mechanism of Cr(VI)-induced apoptosis of CHO cells. Free Radic Res 2004; 38:613-621 (Pubitemid 38697094)
231. Chatterjee M, Wu S: Cell line dependent involvement of ceramide in ultraviolet light-induced apoptosis. Mol Cell Biochem 2001; 219:21-27 (Pubitemid 32331440)
232. Pilane CM, LaBelle EF: NO induced apoptosis of vascular smooth muscle cells accompanied by ceramide increase. J Cell Physiol 2004; 199:310-315 (Pubitemid 38436757)
233. Li YF, Luo ZP: Desipramine antagonized corticosterone-induced apoptosis in cultured PC12 cells. Acta Pharmacol Sin 2002; 23:311-314
234. Li YF, Gong ZH, Yang M, et al: Inhibition of the oligosaccharides extracted from Morinda officinalis, a Chinese traditional herbal medicine, on the corticosterone induced apoptosis in PC12 cells. Life Sci 2003; 72:933-942 (Pubitemid 36001984)
235. Walkinshaw G, Waters CM: Neurotoxin-induced cell death in neuronal PC12 cells is mediated by induction of apoptosis. Neuroscience 1994; 63:975-987 (Pubitemid 24366149)
236. Woodgate A, MacGibbon G, Walton M, et al: The toxicity of 6-hydroxydopamine on PC12 and P19 cells. Brain Res Mol Brain Res 1999; 69:84-92 (Pubitemid 29238189)
237. Angulo J, Cuevas P, Cuevas B, et al: Mechanisms for the inhibition of genital vascular responses by antidepressants in a female rabbit model. J Pharmacol Exp Ther 2004; 310:141-149 (Pubitemid 38812705)
238. Osawa Y, Uchinami H, Bielawski J, et al: Roles for C16-ceramide and sphingosine 1-phosphate in regulating hepatocyte apoptosis in response to tumor necrosis factor-alpha. J Biol Chem 2005; 280:27879-27887 (Pubitemid 41076905)
239. Lacour S, Hammann A, Grazide S, et al: Cisplatin-induced CD95 redistribution into membrane lipid rafts of HT29 human colon cancer cells. Cancer Res 2004; 64:3593-3598 (Pubitemid 38657937)
240. Hashioka S, Klegeris A, Monji A, et al: Antidepressants inhibit interferon-gamma-induced microglial production of IL-6 and nitric oxide. Exp Neurol 2007; 206:33-42 (Pubitemid 46935120)
241. Ferrer I, Marín C, Rey MJ, et al: BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J Neuropathol Exp Neurol 1999; 58:729-739 (Pubitemid 29328502)
242. Lee J, Fukumoto H, Orne J, et al: Decreased levels of BDNF protein in Alzheimer temporal cortex are independent of BDNF polymorphisms. Exp Neurol 2005; 194:91-96 (Pubitemid 40719746)
243. Calabrese F, Molteni R, Maj PF, et al: Chronic duloxetine treatment induces specific changes in the expression of BDNF transcripts and in the subcellular localization of the neurotrophin protein. Neuropsychopharmacology 2007; 32:2351-2359 (Pubitemid 47587673)
244. Fumagalli F, Racagni G, Riva MA: Shedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease. Pharmacogenomics J 2006; 6:95-104
245. Piccinni A, Marazziti D, Catena M, et al: Plasma and serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of antidepressant treatments. J Affect Disord 2008; 105:279-283 (Pubitemid 350245688)
246. Zhang X, Zhang Z, Xie C, et al: Effect of treatment on serum glial cell line-derived neurotrophic factor in depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2008; 32:886-890 (Pubitemid 351312392)
247. Hisaoka K, Nishida A, Koda T, et al: Antidepressant drug treatments induce glial cell line-derived neurotrophic factor (GDNF) synthesis and release in rat C6 glioblastoma cells. J Neurochem 2001; 79:25-34 (Pubitemid 32946639)
248. Shibata SB, Osumi Y, Yagi M, et al: Administration of amitriptyline attenuates noise-induced hearing loss via glial cell line-derived neurotrophic factor (GDNF) induction. Brain Res 2007; 1144:74-81 (Pubitemid 46440849)
249. Hisaoka K, Takebayashi M: [Glia as targets for antidepressants: an involvement in glial cell line-derived neurotrophic factor.] Nihon Shinkei Seishin Yakurigaku Zasshi 2007; 27:173-179 (Japanese)
250. Stahl SM, Shayegan DK: The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. J Clin Psychiatry 2003; 64(suppl 19):6-12
251. Nemeroff CB, Lieberman JA, Weiden PJ, et al: From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr 2005; 10:s1-s20
252. Arango C, Gómez-Beneyto M, Brenlla J, et al: A 6-month prospective, observational, naturalistic, uncontrolled study to evaluate the effectiveness and tolerability of oral ziprasidone in patients with schizophrenia. Eur Neuropsychopharmacol 2007; 17:456-463 (Pubitemid 46509567)
253. Kasckow JW, Mulchahey JJ, Mohamed S: The use of novel antipsychotics in the older patient with neurodegenerative disorders in the long-term care setting. J Am Med Dir Assoc 2004; 5:242-248
254. Battaglia J: Pharmacological management of acute agitation. Drugs 2005; 65:1207-1222
255. Oechsner M, Korchounov A: Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease? Hum Psychopharmacol 2005; 20:203-205
256. Cole SA, Saleem R, Shea WP, et al: Ziprasidone for agitation or psychosis in dementia: four cases. Int J Psychiatry Med 2005; 35:91-98 (Pubitemid 41056528)
257. Wilner KD, Anziano RJ, Johnson AC, et al: The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. J Clin Psychopharmacol 2002; 22:206-210
258. Nemeroff CB: Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry 2005; 66(suppl 8):13-21 (Pubitemid 43004171)
259. Papakostas GI, Petersen TJ, Nierenberg AA, et al: Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry 2004; 65:217-221
260. Cohrs S, Meier A, Neumann AC, et al: Improved sleep continuity and increased slow wave sleep and REM latency during ziprasidone treatment: a randomized, controlled, crossover trial of 12 healthy male subjects. J Clin Psychiatry 2005; 66:989-996 (Pubitemid 41191790)
261. Byerly MJ, Weber MT, Brooks DL, et al: Antipsychotic medications and the elderly: effects on cognition and implications for use. Drugs Aging 2001; 18:45-61
262. Berkowitz A: Ziprasidone for dementia in elderly patients: case review. J Psychiatr Pract 2003; 9:469-473 (Pubitemid 37494259)
263. Daniel DG, Zimbroff DL, Potkin SG, et al: Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999; 20:491-505
264. Arato M, O'Connor R, Meltzer HY, et al: A 1-year, doubleblind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol 2002; 17:207-215
265. Olié JP, Spina E, Murray S, et al: Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. Int Clin Psychopharmacol 2006; 21:143-151 (Pubitemid 43740305)
266. Harvey PD: Ziprasidone and cognition: the evolving story. J Clin Psychiatry 2003; 64(suppl 19):33-39
267. Harvey PD, Siu C, Romano S: Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Psychopharmacology (Berl) 2004; 172:324-332 (Pubitemid 38392326)
268. Loebel A, Siu C, Romano S: Improvement in prosocial functioning after a switch to ziprasidone treatment. CNS Spectr 2004; 9:357-364 (Pubitemid 38649724)
269. Porter RJ, Lunn BS, Walker LL, et al: Cognitive deficit induced by acute tryptophan depletion in patients with Alzheimer's disease. Am J Psychiatry 2000; 157:638-640
270. Porter RJ, Lunn BS, O'Brien JT: Effects of acute tryptophan depletion on cognitive function in Alzheimer's disease and in the healthy elderly. Psychol Med 2003; 33:41-49 (Pubitemid 36113399)
271. Gómez-Esteban JC, Zarranz JJ, Velasco F, et al: Use of ziprasidone in parkinsonian patients with psychosis. Clin Neuropharmacol 2005; 28:111-114 (Pubitemid 40923408)
272. Maurice T, Su TP, Privat A: Sigma1 (sigma 1) receptor agonists and neurosteroids attenuate B25-35-amyloid peptide-induced amnesia in mice through a common mechanism. Neuroscience 1998; 83:413-428
273. Palotás A, Penke B, Palotás M, et al: Haloperidol attenuates beta-amyloid-induced calcium imbalance in human fibroblasts. Skin Pharmacol Physiol 2004; 17:195-199 (Pubitemid 38969845)
274. +-induced mitochondrial damage and cell death by trifluoperazine and W-7 in PC12 cells. Neurochem Int 2005; 46:169-178
275. Lee CS, Park WJ, Ko HH, et al: Differential involvement of mitochondrial permeability transition in cytotoxicity of 1-methyl-4-phenylpyridinium and 6-hydroxydopamine. Mol Cell Biochem 2006; 289:193-200 (Pubitemid 44322489)
276. Lee SJ, Youn YC, Han ES, et al: Depressant effect of mitochondrial respiratory complex inhibitors on proteasome inhibitor-induced mitochondrial dysfunction and cell death in PC12 cells. Neurochem Res 2005; 30:1191-1200 (Pubitemid 41642163)
277. Ozaki N, Tokunage Y, Wakashiro S, et al: Evaluation of cytoprotective drugs for liver preservation by pyridine nucleotide fluorometry. Surgery 1988; 104:98-103
278. Zhelev Z, Ohba H, Bakalova R, et al: Phenothiazines suppress proliferation and induce apoptosis in cultured leukemic cells without any influence on the viability of normal lymphocytes: phenothiazines and leukemia. Cancer Chemother Pharmacol 2004; 53:267-275 (Pubitemid 38293726)
279. Beitner R, Chen-Zion M, Sofer-Bassukevitz Y, et al: Therapeutic and prophylactic treatment of skin burns with several calmodulin antagonists. Gen Pharmacol 1989; 20:165-173 (Pubitemid 19041936)
280. Beitner R, Chen-Zion M, Sofer-Bassukevitz Y, et al: Treatment of frostbite with the calmodulin antagonists thioridazine and trifluoperazine. Gen Pharmacol 1989; 20:641-646 (Pubitemid 19232602)
281. Rodrigues T, Santos AC, Pigoso AA, et al: Thioridazine interacts with the membrane of mitochondria acquiring antioxidant activity toward apoptosis-potentially implicated mechanisms. Br J Pharmacol 2002; 136:136-142 (Pubitemid 34499326)
282. Wang H, Xu H, Dyck LE, et al: Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide (25-35)-induced oxidative stress and the ensuing apoptosis. J Neurosci Res 2005; 81:572-580
283. Pillai A, Parikh V, Terry AV Jr, et al: Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J Psychiatr Res 2007; 41:372-386 (Pubitemid 46201949)
284. Ray SD, Balasubramanian G, Bagchi D, et al: Ca(2+)-calmodulin antagonist chlorpromazine and poly(ADP-ribose) polymerase modulators 4-aminobenzamide and nicotinamide in- fluence hepatic expression of BCL-XL and P53 and protect against acetaminophen-induced programmed and unprogrammed cell death in mice. Free Radic Biol Med 2001; 31:277-291
285. Maeda S, Suzuki A, Lin KH, et al: DNA fragmentation induced in high-cell-density culture of primary rat hepatocytes is an active process dependent on energy availability, gene expression, and calmodulin. J Biochem (Tokyo) 1995; 118:1161-1165 (Pubitemid 26013803)
286. He P, Yan ZL, Wu MC, et al: Chlorpromazine inhibits hepatocyte apoptosis caused by withdrawal of phenobarbital in mice. Zhongguo Yao Li Xue Bao 1999; 20:970-974
287. He J, Xu H, Yang Y, et al: Neuroprotective effects of olanzapine on methamphetamine-induced neurotoxicity are associated with an inhibition of hyperthermia and prevention of Bcl-2 decrease in rats. Brain Res 2004; 1018:186-192 (Pubitemid 38992818)
288. Wang C, McInnis J, Ross-Sanchez M, et al: Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 2001; 107:535-550 (Pubitemid 33097492)
289. Vargas F, Rivas C, Perdomo H, et al: Clozapine prevents apoptosis and enhances receptor dependent respiratory burst in human neutrophils. Pharmazie 2005; 60:364-368 (Pubitemid 40676323)
290. Wei Z, Mousseau DD, Richardson JS, et al: Atypical antipsychotics attenuate neurotoxicity of beta-amyloid(25-35) by modulating Bax and Bcl-X(l/s) expression and localization. J Neurosci Res 2003; 74:942-947
291. +-induced apoptosis. Eur J Neurosci 2003; 17:1563-1570
292. Gnerre C, Kosel M, Baumann P, et al: Interaction of psychotropic drugs with monoamine oxidase in rat brain. J Pharm Pharmacol 2001; 53:1125-1130 (Pubitemid 32754943)
293. Ahlemeyer B, Krieglstein J: Stimulation of 5-HT1A receptor inhibits apoptosis induced by serum deprivation in cultured neurons from chick embryo. Brain Res 1997; 777:179-186 (Pubitemid 28015746)
294. Ahlemeyer B, Glaser A, Schaper C, et al: The 5-HT1A receptor agonist Bay x 3702 inhibits apoptosis induced by serum deprivation in cultured neurons. Eur J Pharmacol 1999; 370:211-216 (Pubitemid 29185110)
295. Druse MJ, Tajuddin NF, Gillespie RA, et al: The serotonin-1A agonist ipsapirone prevents ethanol-associated death of total rhombencephalic neurons and prevents the reduction of fetal serotonin neurons. Brain Res Dev Brain Res 2004; 150:79-88
296. Druse M, Tajuddin NF, Gillespie RA, et al: Signaling pathways involved with serotonin1A agonist-mediated neuroprotection against ethanol-induced apoptosis of fetal rhombencephalic neurons. Brain Res Dev Brain Res 2005; 159:18-28 (Pubitemid 41557710)
297. Terzano MG, Rossi M, Palomba V, et al: New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf 2003; 26:261-282 (Pubitemid 36363607)
298. Devanand DP: Behavioral complications and their treatment in Alzheimer's disease. Geriatrics 1997; 52(suppl 2):S37-S39
299. Bliwise DL: Sleep disorders in Alzheimer's disease and other dementias. Clin Cornerstone 2004; 6(suppl 1A):S16-S28 (Pubitemid 38786663)
300. Cotroneo A, Gareri P, Nicoletti N, et al: Effectiveness and safety of hypnotic drugs in the treatment of insomnia in over 70-year old people. Arch Gerontol Geriatr 2007; 44(suppl 1):121-124 (Pubitemid 46298594)
301. Mattila MJ, Vanakoski J, Kalska H, et al: Effects of alcohol, zolpidem, and some other sedatives and hypnotics on human performance and memory. Pharmacol Biochem Behav 1998; 59:917-923 (Pubitemid 28237904)
302. Katsunuma H, Shimizu T, Ogawa K, et al: Treatment of insomnia by concomitant therapy with zopiclone and aniracetam in patients with cerebral infarction, cerebroatrophy, Alzheimer's disease and Parkinson's disease. Psychiatry Clin Neurosci 1998; 52:198-200 (Pubitemid 28235019)
303. Krystal AD: Treating the health, quality of life, and functional impairments in insomnia. J Clin Sleep Med 2007; 3:63-72
304. Hemmeter U, Müller M, Bischof R, et al: Effect of zopiclone and temazepam on sleep EEG parameters, psychomotor and memory functions in healthy elderly volunteers. Psychopharmacology (Berl) 2000; 147:384-396 (Pubitemid 30048486)
305. Lauterbach EC: Sleep benefit, sleep deprivation, and Parkinsonian depressive subtypes. Am J Psychiatry 1994; 151:782-783
306. Currie LJ, Bennett JP Jr, Harrison MB, et al: Clinical correlates of sleep benefit in Parkinson's disease. Neurology 1997; 48:1115-1117 (Pubitemid 27175652)
307. Merello M, Hughes A, Colosimo C, et al: Sleep benefit in Parkinson's disease. Mov Disord 1997; 12:506-508
308. Tandberg E, Larsen JP, Karlsen K: Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a communitybased study. Mov Disord 1999; 14:922-927
309. Boonstra TW, Stins JF, Daffertshofer A, et al: Effects of sleep deprivation on neural functioning: an integrative review. Cell Mol Life Sci 2007; 64:934-946 (Pubitemid 46597758)
310. Cummings JL, Back C: The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry 1998; 6(suppl 1):S64-S78 (Pubitemid 28194503)
311. Kaufer D: Beyond the cholinergic hypothesis: the effect of metrifonate and other cholinesterase inhibitors on neuropsychiatric symptoms in Alzheimer's disease. Dement Geriatr Cogn Disord 1998; 9(suppl 2):8-14
312. Terry AV Jr, Buccafusco JJ: The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 2003; 306:821-827
313. Tractenberg RE, Singer CM, Kaye JA: Symptoms of sleep disturbance in persons with Alzheimer's disease and normal elderly. J Sleep Res 2005; 14:177-185 (Pubitemid 40813586)
314. Sagaspe P, Sanchez-Ortuno M, Charles A, et al: Effects of sleep deprivation on Color-Word, Emotional, and Specific Stroop interference and on self-reported anxiety. Brain Cogn 2006; 60:76-87
315. Babkoff H, Sing HC, Thorne DR, et al: Perceptual distortions and hallucinations reported during the course of sleep deprivation. Percept Mot Skills 1989; 68(part 1):787-798 (Pubitemid 19155329)
316. Kulisevsky J, Roldan E: Hallucinations and sleep disturbances in Parkinson's disease. Neurology 2004; 63(suppl 3): S28-S30 (Pubitemid 39426257)
317. O'Reilly MF: Functional analysis and treatment of escapemaintained aggression correlated with sleep deprivation. J Appl Behav Anal 1995; 28:225-226
318. Kelly J, Feigenbaum LZ: Another cause of reversible dementia: sleep deprivation due to prostatism. J Am Geriatr Soc 1982; 30:645-646 (Pubitemid 12003747)
319. Chassagne P, Druesne L, Bentot C, et al: [Mental confusion in the elderly.] Presse Med 2005; 34:863-868 (French)
320. Gorissen M, Tielemans M, Coenen A: Alertness and memory after sleep deprivation and diazepam intake. J Psychopharmacol 1997; 11:233-239 (Pubitemid 27375879)
321. Kendall AP, Kautz MA, Russo MB, et al: Effects of sleep deprivation on lateral visual attention. Int J Neurosci 2006; 116:1125-1138 (Pubitemid 44567584)
322. Adam M, Rétey JV, Khatami R, et al: Age-related changes in the time course of vigilant attention during 40 hours without sleep in men. Sleep 2006; 29:55-57 (Pubitemid 44019030)
323. Pilcher JJ, Band D, Odle-Dusseau HN, et al: Human performance under sustained operations and acute sleep deprivation conditions: toward a model of controlled attention. Aviat Space Environ Med 2007; 78(suppl 5):B15-B24 (Pubitemid 46717205)
324. Coenen AM, van Luijtelaar EL: Effects of benzodiazepines, sleep and sleep deprivation on vigilance and memory. Acta Neurol Belg 1997; 97:123-129 (Pubitemid 27293716)
325. Chee MW, Chuah YM: Functional neuroimaging and behavioral correlates of capacity decline in visual short-term memory after sleep deprivation. Proc Natl Acad Sci U S A 2007; 104:9487-9492
326. Fluck E, File SE, Springett J, et al: Does the sedation resulting from sleep deprivation and lorazepam cause similar cognitive deficits? Pharmacol Biochem Behav 1998; 59:909-915
327. Chee MW, Chuah LY, Venkatraman V, et al: Functional imaging of working memory following normal sleep and after 24 and 35 h of sleep deprivation: correlations of fronto-parietal activation with performance. Neuroimage 2006; 31:419-428 (Pubitemid 43728976)
328. Lim J, Choo WC, Chee MW: Reproducibility of changes in behavior and fMRI activation associated with sleep deprivation in a working memory task. Sleep 2007; 30:61-70 (Pubitemid 46098867)
329. Mu Q, Nahas Z, Johnson KA, et al: Decreased cortical response to verbal working memory following sleep deprivation. Sleep 2005; 28:55-67 (Pubitemid 40543120)
330. Casement MD, Broussard JL, Mullington JM, et al: The contribution of sleep to improvements in working memory scanning speed: a study of prolonged sleep restriction. Biol Psychol 2006; 72:208-212
331. Turner TH, Drummond SP, Salamat JS, et al: Effects of 42 hr of total sleep deprivation on component processes of verbal working memory. Neuropsychology 2007; 21:787-795
332. Stickgold R, Walker MP: Memory consolidation and reconsolidation: what is the role of sleep? Trends Neurosci 2005; 28:408-415
333. Huber R: Memory formation: sleep enough before learning. Curr Biol 2007; 17:R367-R368
334. Polzella DJ: Effects of sleep deprivation on short-term recognition memory. J Exp Psychol [Hum Learn] 1975; 104:194-200
335. Tucker MA, Hirota Y, Wamsley EJ, et al: A daytime nap containing solely non-REM sleep enhances declarative but not procedural memory. Neurobiol Learn Mem 2006; 86:241-247 (Pubitemid 44287583)
336. Gais S, Lucas B, Born J: Sleep after learning aids memory recall. Learn Mem 2006; 13:259-262 (Pubitemid 43830669)
337. Raidy DJ, Scharff LF: Effects of sleep deprivation on auditory and visual memory tasks. Percept Mot Skills 2005; 101:451-467
338. Rauchs G, Desgranges B, Foret J, et al: The relationships between memory systems and sleep stages. J Sleep Res 2005; 14:123-140 (Pubitemid 40813581)
339. Wimmer F, Hoffmann RF, Bonato RA, et al: The effects of sleep deprivation on divergent thinking and attention processes. J Sleep Res 1992; 1:223-230 (Pubitemid 23018988)
340. Nilsson JP, Soderstrom M, Karlsson AU, et al: Less effective executive functioning after one night's sleep deprivation. J Sleep Res 2005; 14:1-6 (Pubitemid 40396065)
341. Gottselig JM, Adam M, Retey JV, et al: Random number generation during sleep deprivation: effects of caffeine on response maintenance and stereotypy. J Sleep Res 2006; 15:31-40
342. Chuah YM, Venkatraman V, Dinges DF, et al: The neural basis of interindividual variability in inhibitory efficiency after sleep deprivation. J Neurosci 2006; 26:7156-7162
343. Hsieh S, Cheng IC, Tsai LL: Immediate error correction process following sleep deprivation. J Sleep Res 2007; 16:137-147 (Pubitemid 46850087)
344. Lieberman HR, Bathalon GP, Falco CM, et al: Severe decrements in cognition function and mood induced by sleep loss, heat, dehydration, and undernutrition during simulated combat. Biol Psychiatry 2005; 57:422-429
345. Durmer JS, Dinges DF: Neurocognitive consequences of sleep deprivation. Semin Neurol 2005; 25:117-129
346. Shelton PS, Hocking LB: Zolpidem for dementia-related insomnia and nighttime wandering. Ann Pharmacother 1997; 31:319-322
347. Furuse S, Kanaya N, Takeda T, et al: [Comparison of zopiclone and midazolam premedication for preoperative anxiolysis.] Masui 2002; 51:1094-1099 (Japanese)
348. Rainer MK, Mucke HA, Masching AJ, et al: [State of the art management of BPSD in dementia.] Psychiatr Prax 2005; 32:31-38 (German)
349. Jackson CW, Pitner JK, Mintzer JE: Zolpidem for the treatment of agitation in elderly demented patients. J Clin Psychiatry 1996; 57:372-373 (Pubitemid 26277894)
350. Coccaro EF, Kramer E, Zemishlany Z, et al: Pharmacologic treatment of noncognitive behavioral disturbances in elderly demented patients. Am J Psychiatry 1990; 147:1640-1645
351. Meehan KM, Wang H, David SR, et al: Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology 2002; 26:494-504 (Pubitemid 34260999)
352. Christensen DB, Benfield WR: Alprazolam as an alternative to low-dose haloperidol in older, cognitively impaired nursing facility patients. J Am Geriatr Soc 1998; 46:620-625
353. Ancill RJ, Carlyle WW, Liang RA, et al: Agitation in the demented elderly: a role for benzodiazepines? Int Clin Psychopharmacol 1991; 6:141-146
354. Monroe RR: Anticonvulsants in the treatment of aggression. J Nerv Ment Dis 1975; 160:119-126
355. Yudofsky SC, Silver JM, Hales RE: Pharmacologic management of aggression in the elderly. J Clin Psychiatry 1990; 51(suppl):22-28
356. Volz A, Khorsand V, Gillies D, et al: Benzodiazepines for schizophrenia. Cochrane Database Syst Rev 2007; 1:CD006391
357. Wolkowitz OM, Pickar D: Benzodiazepines in the treatment of schizophrenia: a review and reappraisal. Am J Psychiatry 1991; 148:714-726
358. Wolkowitz OM, Turetsky N, Reus VI, et al: Benzodiazepine augmentation of neuroleptics in treatment-resistant schizophrenia. Psychopharmacol Bull 1992; 28:291-295
359. Krystal A, Fava M, Rubens R, et al: Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. J Clin Sleep Med 2007; 3:48-55 (Pubitemid 46761009)
360. Soares CN, Joffe H, Rubens R, et al: Eszopiclone in patients with insomnia during perimenopause and early postmenopause: a randomized controlled trial. Obstet Gynecol 2006; 108:1402-1410 (Pubitemid 44901014)
361. Kajimura N, Kato M, Okuma T, et al: Effects of zopiclone on sleep and symptoms in schizophrenia: comparison with benzodiazepine hypnotics. Prog Neuropsychopharmacol Biol Psychiatry 1994; 18:477-490 (Pubitemid 24161566)
362. Kato M, Kajimura N, Okuma T, et al: Association between delta waves during sleep and negative symptoms in schizophrenia: pharmaco-EEG studies by using structurally different hypnotics. Neuropsychobiology 1999; 39:165-172 (Pubitemid 29161085)
363. Louzada PR, Lima AC, Mendonca-Silva DL, et al: Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer's disease and other neurological disorders. FASEB J 2004; 18:511-518
364. García-Santos G, Herrera F, Martin V, et al: Antioxidant activity and neuroprotective effects of zolpidem and several synthesis intermediates. Free Radic Res 2004; 38:1289-1299 (Pubitemid 40045481)
365. Bishnoi M, Chopra K, Kulkarni SK: Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1130-1138 (Pubitemid 46810111)
366. Berson A, Descatoire V, Sutton A, et al: Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation. J Pharmacol Exp Ther 2001; 299:793-800
367. Galeffi F, Sinnar S, Schwartz-Bloom RD: Diazepam promotes ATP recovery and prevents cytochrome c release in hippocampal slices after in vitro ischemia. J Neurochem 2000; 75:1242-1249 (Pubitemid 30660514)
368. Benedetti F, Serretti A, Colombo C, et al: A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci Lett 2004; 368:123-126 (Pubitemid 39194855)
369. Sehgal A, Joiner W, Crocker A, et al: Molecular analysis of sleep: wake cycles in Drosophila. Cold Spring Harb Symp Quant Biol 2007; 72:557-564
370. Kumar A, Singh A: Protective effect of St. John's wort (Hypericum perforatum) extract on 72-hour sleep deprivation-induced anxiety-like behavior and oxidative damage in mice. Planta Med 2007; 73:1358-1364
371. Cirelli C, Tononi G: Uncoupling proteins and sleep deprivation. Arch Ital Biol 2004; 142:541-549
372. Sei H, Saitoh D, Yamamoto K, et al: Differential effect of short-term REM sleep deprivation on NGF and BDNF protein levels in the rat brain. Brain Res 2000; 877:387-390
373. Hairston IS, Peyron C, Denning DP, et al: Sleep deprivation effects on growth factor expression in neonatal rats: a potential role for BDNF in the mediation of delta power. J Neurophysiol 2004; 91:1586-1595 (Pubitemid 38339331)
374. Kato K, Hirai K, Nishiyama K, et al: Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist. Neuropharmacology 2005; 48:301-310
375. Roth T, Seiden D, Sainati S, et al: Effects of ramelteon on patient-reported sleep latency in older adults with chronic insomnia. Sleep Med 2006; 7:312-318 (Pubitemid 43792892)
376. Mini LJ, Wang-Weigand S, Zhang J: Self-reported efficacy and tolerability of ramelteon 8 mg in older adults experiencing severe sleep-onset difficulty. Am J Geriatr Pharmacother 2007; 5:177-184 (Pubitemid 350048506)
377. Brismar K, Mogensen L, Wetterberg L: Depressed melatonin secretion in patients with nightmares due to beta-adrenoceptor blocking drugs. Acta Med Scand 1987; 221:155-158 (Pubitemid 17072874)
378. Silber MH, Hansen MR, Girish M: Complex nocturnal visual hallucinations. Sleep Med 2005; 6:363-366
379. Fisher AA, Davis M, Jeffery I: Acute delirium induced by metoprolol. Cardiovasc Drugs Ther 2002; 16:161-165
380. Chan-Palay V, Asan E: Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 1989; 287:373-392 (Pubitemid 19239069)
381. Szot P, White SS, Greenup JL, et al: Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimer's disease and dementia with Lewy bodies. J Neurosci 2006; 26:467-478 (Pubitemid 43237111)
382. Olde Rikkert MG, Rigaud AS: Melatonin in elderly patients with insomnia: a systematic review. Z Gerontol Geriatr 2001; 34:491-497 (Pubitemid 34087425)
383. Jansen SL, Forbes DA, Duncan V, et al: Melatonin for cognitive impairment. Cochrane Database Syst Rev 2006; 1:CD003802
384. Arushanian EB, Baida OA, Mastiagin SS: [Effect of melatonin on memory, individual time perception, and anxiety in young people of different chronotype groups.] Eksp Klin Farmakol 2006; 69:21-23 (Russian)
385. Hanania M, Kitain E: Melatonin for treatment and prevention of postoperative delirium. Anesth Analg 2002; 94:338-339 (Pubitemid 34106824)
386. Cohen-Mansfield J, Garfinkel D, Lipson S: Melatonin for treatment of sundowning in elderly persons with dementia: a preliminary study. Arch Gerontol Geriatr 2000; 31:65-76
387. Suhner A, Schlagenhauf P, Tschopp A, et al: Impact of melatonin on driving performance. J Travel Med 1998; 5:7-13
388. Cavallo A, Ris MD, Succop P, et al: Melatonin treatment of pediatric residents for adaptation to night shift work. Ambul Pediatr 2005; 5:172-177 (Pubitemid 40852132)
389. Gorfine T, Yeshurun Y, Zisapel N: Nap and melatonin-induced changes in hippocampal activation and their role in verbal memory consolidation. J Pineal Res 2007; 43:336-342 (Pubitemid 47512264)
390. Boeve BF, Silber MH, Ferman TJ: Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 2003; 4:281-284
391. Serrano C, García-Borreguero D: Fluctuations in cognition and alertness in Parkinson's disease and dementia. Neurology 2004; 63(suppl 3):S31-S34 (Pubitemid 39426258)
392. Iacovitti L, Stull ND, Johnston K: Melatonin rescues dopamine neurons from cell death in tissue culture models of oxidative stress. Brain Res 1997; 768:317-326 (Pubitemid 27433507)
393. Coulom H, Birman S: Chronic exposure to rotenone models sporadic Parkinson's disease in Drosophila melanogaster. J Neurosci 2004; 24:10993-10998
394. McMillan CR, Sharma R, Ottenhof T, et al: Modulation of tyrosine hydroxylase expression by melatonin in human SH-SY5Y neuroblastoma cells. Neurosci Lett 2007; 419:202-206 (Pubitemid 46755488)
395. Sharma R, McMillan CR, Niles LP: Neural stem cell transplantation and melatonin treatment in a 6-hydroxydopamine model of Parkinson's disease. J Pineal Res 2007; 43:245-254 (Pubitemid 47353003)
396. +-induced neurodegeneration and glutathione impairment in the nigrostriatal dopaminergic pathway. J Pineal Res 2002; 32:262-269
397. +) neurotoxicity in rats. Neurosci Lett 1998; 245:61-64
398. Sharma R, McMillan CR, Tenn CC, et al: Physiological neuroprotection by melatonin in a 6-hydroxydopamine model of Parkinson's disease. Brain Res 2006; 1068:230-236 (Pubitemid 43139282)
399. Kim YS, Joo WS, Jin BK, et al: Melatonin protects 6-OHDA-induced neuronal death of nigrostriatal dopaminergic system. Neuroreport 1998; 9:2387-2390 (Pubitemid 28338239)
400. Sharma SK, Ebadi M: Metallothionein attenuates 3-morpholinosydnonimine (SIN-1)-induced oxidative stress in dopaminergic neurons. Antioxid Redox Signal 2003; 5:251-264
401. Ebadi M, Sharma SK, Ghafourifar P, et al: Peroxynitrite in the pathogenesis of Parkinson's disease and the neuroprotective role of metallothioneins. Methods Enzymol 2005; 396:276-298 (Pubitemid 41603553)
402. Antolin I, Mayo JC, Sainz RM, et al: Protective effect of melatonin in a chronic experimental model of Parkinson's disease. Brain Res 2002; 943:163-173 (Pubitemid 36120376)
403. Acuña-Castroviejo D, Coto-Montes A, Gaia Monti M, et al: Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci 1997; 60:PL23-PL29 (Pubitemid 27022724)
404. Joo WS, Jin BK, Park CW, et al: Melatonin increases striatal dopaminergic function in 6-OHDA-lesioned rats. Neuroreport 1998; 9:4123-4126
405. Singh S, Ahmed R, Sagar RK, et al: Neuroprotection of the nigrostriatal dopaminergic neurons by melatonin in hemiparkinsonium rat. Indian J Med Res 2006; 124:419-426 (Pubitemid 46603377)
406. Ortiz GG, Crespo-Lopez ME, Moran-Moguel C, et al: Protective role of melatonin against MPTP-induced mouse brain cell DNA fragmentation and apoptosis in vivo. Neuro Endocrinol Lett 2001; 22:101-108 (Pubitemid 32396388)
407. Ishido M: Melatonin inhibits maneb-induced aggregation of alpha-synuclein in rat pheochromocytoma cells. J Pineal Res 2007; 42:125-130
408. Lin CH, Huang JY, Ching CH, et al: Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone-induced parkinsonian rats. J Pineal Res 2008; 44:205-213
409. Zhu LQ, Wang SH, Ling ZQ, et al: Effect of inhibiting melatonin biosynthesis on spatial memory retention and tau phosphorylation in rat. J Pineal Res 2004; 37:71-77 (Pubitemid 39120209)
410. Zhu LQ, Wang SH, Ling ZQ, et al: Inhibition of melatonin biosynthesis activates protein kinase a and induces Alzheimer-like tau hyperphosphorylation in rats. Chin Med Sci J 2005; 20:83-87 (Pubitemid 41058481)
411. Wang JZ, Wang ZF: Role of melatonin in Alzheimer-like neurodegeneration. Acta Pharmacol Sin 2006; 27:41-49
412. Cheng Y, Feng Z, Zhang QZ, et al: Beneficial effects of melatonin in experimental models of Alzheimer disease. Acta Pharmacol Sin 2006; 27:129-139 (Pubitemid 43171149)
413. Olivieri G, Brack C, Muller-Spahn F, et al: Mercury induces cell cytotoxicity and oxidative stress and increases beta-amyloid secretion and tau phosphorylation in SHSY5Y neuroblastoma cells. J Neurochem 2000; 74:231-236 (Pubitemid 30012773)
414. Gutierrez-Cuesta J, Sureda FX, Romeu M, et al: Chronic administration of melatonin reduces cerebral injury biomarkers in SAMP8. J Pineal Res 2007; 42:394-402 (Pubitemid 46581664)
415. Yin J, Liu YH, Xu YF, et al: Melatonin arrests peroxynitrite-induced tau hyperphosphorylation and the overactivation of protein kinases in rat brain. J Pineal Res 2006; 41:124-129 (Pubitemid 44141746)
416. Liu SJ, Wang JZ: Alzheimer-like tau phosphorylation induced by wortmannin in vivo and its attenuation by melatonin. Acta Pharmacol Sin 2002; 23:183-187
417. Deng YQ, Xu GG, Duan P, et al: Effects of melatonin on wortmannin-induced tau hyperphosphorylation. Acta Pharmacol Sin 2005; 26:519-526 (Pubitemid 40676159)
418. Wang DL, Ling ZQ, Cao FY, et al: Melatonin attenuates isoproterenol-induced protein kinase A overactivation and tau hyperphosphorylation in rat brain. J Pineal Res 2004; 37:11-16
419. Li XC, Wang ZF, Zhang JX, et al: Effect of melatonin on calyculin A-induced tau hyperphosphorylation. Eur J Pharmacol 2005; 510:25-30 (Pubitemid 40312386)
420. Matsubara E, Bryant-Thomas T, Pacheco Quinto J, et al: Melatonin increases survival and inhibits oxidative and amyloid pathology in a transgenic model of Alzheimer's disease. J Neurochem 2003; 85:1101-1108 (Pubitemid 36613258)
421. Cheng X, van Breemen RB: Mass spectrometry-based screening for inhibitors of beta-amyloid protein aggregation. Anal Chem 2005; 77:7012-7015 (Pubitemid 41547299)
422. Brusco LI, Marquez M, Cardinali DP: Monozygotic twins with Alzheimer's disease treated with melatonin: case report. J Pineal Res 1998; 25:260-263 (Pubitemid 29029904)
423. Reiter RJ: Oxidative damage in the central nervous system: protection by melatonin. Prog Neurobiol 1998; 56:359-384 (Pubitemid 28389724)
424. Jou MJ, Peng TI, Reiter RJ, et al: Visualization of the antioxidative effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes. J Pineal Res 2004; 37:55-70
425. Ciuffi M, Pisanello M, Pagliai G, et al: Antioxidant protection in cultured corneal cells and whole corneas submitted to UV-B exposure. J Photochem Photobiol B 2003; 71:59-68 (Pubitemid 37258832)
426. Thomas B, Mohanakumar KP: Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatum. J Pineal Res 2004; 36:25-32
427. Imam SZ, el-Yazal J, Newport GD, et al: Methamphetamine-induced dopaminergic neurotoxicity: role of peroxynitrite and neuroprotective role of antioxidants and peroxynitrite decomposition catalysts. Ann N Y Acad Sci 2001; 939:366-380
428. Lezoualc'h F, Sparapani M, Behl C: N-acetyl-serotonin (normelatonin) and melatonin protect neurons against oxidative challenges and suppress the activity of the transcription factor NF-kappaB. J Pineal Res 1998; 24:168-178
429. Herrera F, Sainz RM, Mayo JC, et al: Glutamate induces oxidative stress not mediated by glutamate receptors or cystine transporters: protective effect of melatonin and other antioxidants. J Pineal Res 2001; 31:356-362 (Pubitemid 33032952)
430. Mayo JC, Sainz RM, Uria H, et al: Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson's disease. J Pineal Res 1998; 24:179-192 (Pubitemid 28156603)
431. Miller JW, Selhub J, Joseph JA: Oxidative damage caused by free radicals produced during catecholamine autoxidation: protective effects of O-methylation and melatonin. Free Radic Biol Med 1996; 21:241-249 (Pubitemid 26255201)
432. Khaldy H, Escames G, León J, et al: Comparative effects of melatonin, L-deprenyl, Trolox and ascorbate in the suppression of hydroxyl radical formation during dopamine autoxidation in vitro. J Pineal Res 2000; 29:100-107
433. Rocchitta G, Migheli R, Esposito G, et al: Endogenous melatonin protects l-DOPA from autoxidation in the striatal extracellular compartment of the freely moving rat: potential implication for long-term l-DOPA therapy in Parkinson's disease. J Pineal Res 2006; 40:204-213 (Pubitemid 43344656)
434. Maharaj H, Sukhdev Maharaj D, Scheepers M, et al: l-DOPA administration enhances 6-hydroxydopamine generation. Brain Res 2005; 1063:180-186 (Pubitemid 41741029)
435. Andrabi SA, Sayeed I, Siemen D, et al: Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin. FASEB J 2004; 18:869-871
436. Han YX, Zhang SH, Wang XM, et al: Inhibition of mitochondria responsible for the anti-apoptotic effects of melatonin during ischemia-reperfusion. J Zhejiang Univ Sci B 2006; 7:142-147
437. Leon J, Acuna-Castroviejo D, Escames G, et al: Melatonin mitigates mitochondrial malfunction. J Pineal Res 2005; 38:1-9
438. Saravanan KS, Sindhu KM, Mohanakumar KP: Melatonin protects against rotenone-induced oxidative stress in a hemiparkinsonian rat model. J Pineal Res 2007; 42:247-253 (Pubitemid 46365061)
439. Absi E, Ayala A, Machado A, et al: Protective effect of melatonin against the 1-methyl-4-phenylpyridinium-induced inhibition of complex I of the mitochondrial respiratory chain. J Pineal Res 2000; 29:40-47 (Pubitemid 30449700)
440. Martin M, Macias M, Escames G, et al: Melatonin-induced increased activity of the respiratory chain complexes I and IV can prevent mitochondrial damage induced by ruthenium red in vivo. J Pineal Res 2000; 28:242-248 (Pubitemid 30255377)
441. Dabbeni-Sala F, Di Santo S, Franceschini D, et al: Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. FASEB J 2001; 15:164-170 (Pubitemid 32061667)
442. Fosslien E: Mitochondrial medicine-molecular pathology of defective oxidative phosphorylation. Ann Clin Lab Sci 2001; 31:25-67 (Pubitemid 32097212)
443. Martin M, Macias M, Leon J, et al: Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. Int J Biochem Cell Biol 2002; 34:348-357 (Pubitemid 34164278)
444. Okatani Y, Wakatsuki A, Reiter RJ: Melatonin protects hepatic mitochondrial respiratory chain activity in senescenceaccelerated mice. J Pineal Res 2002; 32:143-148 (Pubitemid 34309880)
445. Acuna-Castroviejo D, Escames G, Leon J, et al: Mitochondrial regulation by melatonin and its metabolites. Adv Exp Med Biol 2003; 527:549-557 (Pubitemid 38197684)
446. Khaldy H, Escames G, León J, et al: Synergistic effects of melatonin and deprenyl against MPTP-induced mitochondrial damage and DA depletion. Neurobiol Aging 2003; 24:491-500 (Pubitemid 36205054)
447. Scott AE, Cosma GN, Frank AA, et al: Disruption of mitochondrial respiration by melatonin in MCF-7 cells. Toxicol Appl Pharmacol 2001; 171:149-156
448. Kolker S, Ahlemeyer B, Krieglstein J, et al: Contribution of reactive oxygen species to 3-hydroxyglutarate neurotoxicity in primary neuronal cultures from chick embryo telencephalons. Pediatr Res 2001; 50:76-82 (Pubitemid 32566577)
449. Park JW, Youn YC, Kwon OS, et al: Protective effect of serotonin on 6-hydroxydopamine- and dopamine-induced oxidative damage of brain mitochondria and synaptosomes and PC12 cells. Neurochem Int 2002; 40:223-233 (Pubitemid 34015871)
450. Lee CS, Park SY, Ko HH, et al: Effect of change in cellular GSH levels on mitochondrial damage and cell viability loss due to mitomycin c in small cell lung cancer cells. Biochem Pharmacol 2004; 68:1857-1867
451. Vassilopoulos A, Papazafiri P: Attenuation of oxidative stress in HL-1 cardiomyocytes improves mitochondrial function and stabilizes Hif-1alpha. Free Radic Res 2005; 39:1273-1284 (Pubitemid 43023792)
452. Weinreb O, Mandel S, Youdim MB: cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells. FASEB J 2003; 17:935-937
453. Weinreb O, Mandel S, Youdim MB: Gene and protein expression profiles of anti- and pro-apoptotic actions of dopamine, R-apomorphine, green tea polyphenol (-)-epigallocatechine-3-gallate, and melatonin. Ann N Y Acad Sci 2003; 993:351-361 (Pubitemid 36808465)
454. Alvira D, Tajes M, Verdaguer E, et al: Inhibition of the cdk5/p25 fragment formation may explain the antiapoptotic effects of melatonin in an experimental model of Parkinson's disease. J Pineal Res 2006; 40:251-258 (Pubitemid 43348546)
455. Mayo JC, Sainz RM, Antolín I, et al: Ultrastructural confirmation of neuronal protection by melatonin against the neurotoxin 6-hydroxydopamine cell damage. Brain Res 1999; 818:221-227 (Pubitemid 29229935)
456. +-induced caspase-mediated death pathway and DNA fragmentation factor-45 cleavage in SK-N-SH cultured cells. J Pineal Res 2007; 43:115-120
457. Uz T, Giusti P, Franceschini D, et al: Protective effect of melatonin against hippocampal DNA damage induced by intraperitoneal administration of kainate to rats. Neuroscience 1996; 73:631-636 (Pubitemid 26260925)
458. Chen ST, Chuang JI: The antioxidant melatonin reduces cortical neuronal death after intrastriatal injection of kainate in the rat. Exp Brain Res 1999; 124:241-247
459. Das A, Belagodu A, Reiter RJ, et al: Cytoprotective effects of melatonin on C6 astroglial cells exposed to glutamate excitotoxicity and oxidative stress. J Pineal Res 2008; 45:117-124
460. Feng Z, Zhang JT: Protective effect of melatonin on betaamyloid- induced apoptosis in rat astroglioma C6 cells and its mechanism. Free Radic Biol Med 2004; 37:1790-1801 (Pubitemid 39441063)
461. + treatment in human astrocytoma U373MG cells. J Pineal Res 2004; 36:117-125
462. Niles LP, Armstrong KJ, Rincón Castro LM, et al: Neural stem cells express melatonin receptors and neurotrophic factors: colocalization of the MT1 receptor with neuronal and glial markers. BMC Neurosci 2004; 28:5:41
463. Castro LM, Gallant M, Niles LP: Novel targets for valproic acid: up-regulation of melatonin receptors and neurotrophic factors in C6 glioma cells. J Neurochem 2005; 95:1227-1236 (Pubitemid 41779249)
464. Kong X, Li X, Cai Z, et al: Melatonin regulates the viability and differentiation of rat midbrain neural stem cells. Cell Mol Neurobiol 2008; 28:569-579 (Pubitemid 351624509)
465. Armstrong KJ, Niles LP: Induction of GDNF mRNA expression by melatonin in rat C6 glioma cells. Neuroreport 2002; 13:473-475 (Pubitemid 34293193)
466. Imbesi M, Uz T, Dzitoyeva S, et al: Stimulatory effects of a melatonin receptor agonist, ramelteon, on BDNF in mouse cerebellar granule cells. Neurosci Lett 2008; 439:34-36
467. Atri A, Shaughnessy LW, Locascio JJ, et al: Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord 2008; 22:209-221
468. Tol J, Koopman M, Cats A, et al: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360:563-572
469. Lauterbach EC, Victoroff J, Coburn KL, et al: Psychopharmacological neuroprotection in neurodegenerative disease: assessing the preclinical data. J Neuropsychiatry Clin Neurosci 2010; 22:8-18